Molibresib besylate

• CAT Number: I019144
• CAS Number: 1895049-20-3
• Molecular Formula: C₂₈H₂₈ClN₅O₅S
• Molecular Weight: 582.07
• Purity: ≥95%
• Target: Epigenetic Reader Domain
• IUPAC Name: benzenesulfonic acid;2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide
• InChI: InChI=1S/C22H22ClN5O2.C6H6O3S/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14;7-10(8,9)6-4-2-1-3-5-6/h5-11,18H,4,12H2,1-3H3,(H,24,29);1-5H,(H,7,8,9)/t18-;/m0./s1
• InChIKey: UQGMFOYDYUZADE-FERBBOLQSA-N
• SMILES: CCNC(=O)C[C@H]1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C.C1=CC=C(C=C1)S(=O)(=O)O

Molibresib besylate(CAT: I019144) is a potent and selective inhibitor of bromodomain and extraterminal (BET) proteins, including BRD2, BRD3, and BRD4, which are critical regulators of transcriptional activity. By disrupting the interaction between acetylated histones and BET proteins, it suppresses the expression of oncogenes and cell cycle regulators. Molibresib is extensively studied in cancer research, particularly for treating hematological malignancies and solid tumors, where BET protein activity drives tumor progression. Its ability to modulate epigenetic pathways provides valuable insights into transcriptional regulation and supports the development of novel therapies targeting cancers and other diseases associated with dysregulated BET signaling.